ニューロサイエンス市場：タイプ別、エンドユーザー別-2025～2030年の世界予測

ニューロサイエンス市場の2023年の市場規模は137億7,000万米ドルで、2024年には151億1,000万米ドルに達すると予測され、CAGR 10.34%で成長し、2030年には274億2,000万米ドルに達すると予測されています。

市場調査領域としてのニューロサイエンスの範囲は、人間の脳機能を理解し強化するための生物学と認知科学の研究と応用を包含します。このセグメントの必要性は、神経疾患、精神衛生上の課題、変性疾患を治療するソリューションに対する需要の高まりから生じています。用途は医薬品、バイオテクノロジー、認知ニューロサイエンス、ニューロ技術に及び、最終用途セグメントは医療、教育、防衛などです。市場成長は、脳イメージングにおける技術的進歩、神経学研究への資金提供の増加、メンタルヘルスに対する意識の高まりといった要因に影響されています。人工知能や機械学習技術の流入は、メンタル医療におけるパーソナライズされた治療計画や予測分析などの技術革新に大きな機会をもたらします。さらに、COVID-19の大流行による遠隔医療サービスの拡大により、遠隔医療環境におけるニューロサイエンス主導型アプリケーションの統合が加速しています。しかし、研究開発コストの高さ、規制上のハードル、ニューロ技術の進歩をめぐる倫理的配慮などの課題も残っています。さらに、市場はセグメント化されており、少数の有力参入企業と多数のニッチ開発者が競争圧力を高めています。技術革新の機が熟しているセグメントには、非侵襲的神経刺激技術の開発、ブレイン・コンピューター・インターフェース技術の強化、サイケデリック物質の治療可能性と神経への影響の探求などがあります。大学や研究機関との連携を活用し、学際的研究を促進し、患者中心のアプローチを製品開発に優先させることで、事業の成長はさらに強化されます。市場は本質的にダイナミックで急速な進化を遂げているため、企業は常に新たな動向や規制の変更に注意を払う必要があります。従って、ニューロサイエンス市場の性質は、高いイノベーションの可能性によって特徴付けられるが、収益化と倫理的展開における課題によって緩和されており、調査への注力と市場の俊敏性を戦略的に融合させる必要があります。

市場力学：急速に進化するニューロサイエンス市場の主要市場洞察を公開

ニューロサイエンス市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の神経疾患の有病率の増加
  • 神経疾患に対する創薬と薬剤開発の増加
  • 脳の健康と認知機能を高めるためのニューロサイエンスの使用の増加
• 市場抑制要因
  • ニューロサイエンス調査に伴う高コスト
• 市場機会
  • 個別化医療の開発におけるニューロサイエンスの利用拡大
  • ニューロサイエンス研究のための有利な資金状況
• 市場課題
  • ニューロ技術の使用に関する機能制限

ポーターのファイブフォース：ニューロサイエンス市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ニューロサイエンス市場における外部からの影響の把握

外部マクロ環境要因は、ニューロサイエンス市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：ニューロサイエンス市場における競合情勢の把握

ニューロサイエンス市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：ニューロサイエンス市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ニューロサイエンス市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：ニューロサイエンス市場における成功への道筋を描く

ニューロサイエンス市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で神経疾患の罹患率が増加
    • 神経疾患に対する新薬の発見と開発の増加
    • 脳の健康と認知機能を高めるためのニューロサイエンスの使用増加
  • 抑制要因
    • ニューロサイエンス調査に関連する高コスト
  • 機会
    • 個別化医療の開発におけるニューロサイエンスの新たな利用
    • ニューロサイエンス研究のための好ましい資金調達情勢
  • 課題
    • 神経技術の使用に関する機能的制限
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 ニューロサイエンス市場：タイプ別

• イントロダクション
• 診断ソリューション
  • 分子
    • 免疫測定
    • 機器
    • キットと消耗品
    • 液体クロマトグラフィー
    • PCR
    • シーケンシング
    • ソフトウェア
  • 非分子
    • 脳幹聴覚誘発電位
    • 脳波検査
    • イメージング
• 薬物療法
  • 神経疾患
    • アルツハイマー病
    • てんかん
    • ハンチントン病
    • 多発性硬化症
    • パーキンソン病
    • 血管性認知症
  • 神経精神疾患
    • 不安症
    • 注意欠陥
    • 自閉症スペクトラム
    • 不眠症
    • 気分障害
    • 薬剤乱用
• 非薬物療法
  • 行動療法
    • 動物介在
    • 在宅勤務
    • 入院患者
    • 外来患者
  • デジタルヘルスサービス

第7章 ニューロサイエンス市場：エンドユーザー別

• イントロダクション
• 診断ラボ
• 病院
• 研究・学術機関

第8章 南北アメリカのニューロサイエンス市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋のニューロサイエンス市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのニューロサイエンス市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Agilent Technologies, Inc.
• Bayer AG
• Bio-Rad Laboratories, Inc.
• Brain Products GmbH
• Compumedics Limited
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilson, Inc.
• GL Sciences Inc.
• Hitachi, Ltd.
• Illumina, Inc.
• JASCO Corporation
• Merck KGaA
• Metrohm AG
• Natus Medical Incorporated
• Novasep Holding SAS
• PerkinElmer Inc.
• Pfizer Inc.
• Promega Corporation
• QIAGEN GmbH
• Restek Corporation
• Shimadzu Corporation
• Siemens AG
• Thermo Fisher Scientific Inc.
• Waters Corporation
• YMC Co., Ltd.

LIST OF FIGURES

• FIGURE 1. NEUROSCIENCE MARKET RESEARCH PROCESS
• FIGURE 2. NEUROSCIENCE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NEUROSCIENCE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NEUROSCIENCE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NEUROSCIENCE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NEUROSCIENCE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NEUROSCIENCE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES NEUROSCIENCE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES NEUROSCIENCE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. NEUROSCIENCE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. NEUROSCIENCE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NEUROSCIENCE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NEUROSCIENCE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NEUROSCIENCE MARKET DYNAMICS
• TABLE 7. GLOBAL NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NEUROSCIENCE MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NEUROSCIENCE MARKET SIZE, BY KITS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NEUROSCIENCE MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NEUROSCIENCE MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NEUROSCIENCE MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NEUROSCIENCE MARKET SIZE, BY BRAINSTEM AUDITORY EVOKED POTENTIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL NEUROSCIENCE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL NEUROSCIENCE MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL NEUROSCIENCE MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL NEUROSCIENCE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL NEUROSCIENCE MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL NEUROSCIENCE MARKET SIZE, BY VASCULAR DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANXIETY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL NEUROSCIENCE MARKET SIZE, BY ATTENTION DEFICIT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL NEUROSCIENCE MARKET SIZE, BY AUTISM SPECTRUM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL NEUROSCIENCE MARKET SIZE, BY INSOMNIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL NEUROSCIENCE MARKET SIZE, BY MOOD DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL NEUROSCIENCE MARKET SIZE, BY SUBSTANCE ABUSE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANIMAL-ASSISTED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOME-BASED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL NEUROSCIENCE MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL NEUROSCIENCE MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIGITAL HEALTH SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 57. AMERICAS NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 58. AMERICAS NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 59. AMERICAS NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 60. AMERICAS NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 61. AMERICAS NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 62. AMERICAS NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 63. AMERICAS NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 64. AMERICAS NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. AMERICAS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 66. ARGENTINA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. ARGENTINA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 68. ARGENTINA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 69. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 70. ARGENTINA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 71. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 72. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 73. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 74. ARGENTINA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 75. ARGENTINA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. BRAZIL NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. BRAZIL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 78. BRAZIL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 79. BRAZIL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 80. BRAZIL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 81. BRAZIL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 82. BRAZIL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 83. BRAZIL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 84. BRAZIL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 85. BRAZIL NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. CANADA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. CANADA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 88. CANADA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 89. CANADA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 90. CANADA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 91. CANADA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 92. CANADA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 93. CANADA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 94. CANADA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 95. CANADA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. MEXICO NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. MEXICO NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 98. MEXICO NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 99. MEXICO NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 100. MEXICO NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 101. MEXICO NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 102. MEXICO NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 103. MEXICO NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 104. MEXICO NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 105. MEXICO NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. UNITED STATES NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. UNITED STATES NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 108. UNITED STATES NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 109. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 110. UNITED STATES NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 111. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 112. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 113. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 114. UNITED STATES NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 115. UNITED STATES NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. UNITED STATES NEUROSCIENCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 119. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 120. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 121. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 122. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 123. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 124. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 125. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 126. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 128. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 130. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 131. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 132. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 133. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 134. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 135. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 136. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 137. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. CHINA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. CHINA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 140. CHINA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 141. CHINA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 142. CHINA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 143. CHINA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 144. CHINA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 145. CHINA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 146. CHINA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 147. CHINA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. INDIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. INDIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 150. INDIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 151. INDIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 152. INDIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 153. INDIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 154. INDIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 155. INDIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 156. INDIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 157. INDIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. INDONESIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. INDONESIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 160. INDONESIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 161. INDONESIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 162. INDONESIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 163. INDONESIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 164. INDONESIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 165. INDONESIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 166. INDONESIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 167. INDONESIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. JAPAN NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 169. JAPAN NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 170. JAPAN NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 171. JAPAN NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 172. JAPAN NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 173. JAPAN NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 174. JAPAN NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 175. JAPAN NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 176. JAPAN NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 177. JAPAN NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. MALAYSIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. MALAYSIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 180. MALAYSIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 181. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 182. MALAYSIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 183. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 184. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 185. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 186. MALAYSIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 187. MALAYSIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 190. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 191. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 192. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 193. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 194. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 195. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 196. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 197. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 198. SINGAPORE NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 199. SINGAPORE NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 200. SINGAPORE NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 201. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 202. SINGAPORE NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 203. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 204. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 205. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 206. SINGAPORE NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 207. SINGAPORE NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 211. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 212. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 213. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 214. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 215. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 216. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 217. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 218. TAIWAN NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 219. TAIWAN NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 220. TAIWAN NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 221. TAIWAN NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 222. TAIWAN NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 223. TAIWAN NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 224. TAIWAN NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 225. TAIWAN NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 226. TAIWAN NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 227. TAIWAN NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 228. THAILAND NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 229. THAILAND NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 230. THAILAND NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 231. THAILAND NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 232. THAILAND NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 233. THAILAND NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 234. THAILAND NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 235. THAILAND NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 236. THAILAND NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 237. THAILAND NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 238. VIETNAM NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 239. VIETNAM NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 240. VIETNAM NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 241. VIETNAM NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 242. VIETNAM NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 243. VIETNAM NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 244. VIETNAM NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 245. VIETNAM NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 246. VIETNAM NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 247. VIETNAM NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 253. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 254. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 255. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 256. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 257. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 258. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 259. DENMARK NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 260. DENMARK NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 261. DENMARK NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 262. DENMARK NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 263. DENMARK NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 264. DENMARK NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 265. DENMARK NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 266. DENMARK NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 267. DENMARK NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 268. DENMARK NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 269. EGYPT NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 270. EGYPT NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 271. EGYPT NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 272. EGYPT NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 273. EGYPT NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 274. EGYPT NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 275. EGYPT NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 276. EGYPT NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 277. EGYPT NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 278. EGYPT NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 279. FINLAND NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 280. FINLAND NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 281. FINLAND NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 282. FINLAND NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 283. FINLAND NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 284. FINLAND NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 285. FINLAND NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 286. FINLAND NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 287. FINLAND NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 288. FINLAND NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 289. FRANCE NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 290. FRANCE NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 291. FRANCE NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 292. FRANCE NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 293. FRANCE NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 294. FRANCE NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 295. FRANCE NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 296. FRANCE NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 297. FRANCE NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 298. FRANCE NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 299. GERMANY NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 300. GERMANY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 301. GERMANY NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 302. GERMANY NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 303. GERMANY NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 304. GERMANY NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 305. GERMANY NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 306. GERMANY NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 307. GERMANY NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 308. GERMANY NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 309. ISRAEL NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 310. ISRAEL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 311. ISRAEL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 312. ISRAEL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 313. ISRAEL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 314. ISRAEL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 315. ISRAEL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 316. ISRAEL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 317. ISRAEL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 318. ISRAEL NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 319. ITALY NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 320. ITALY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 321. ITALY NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 322. ITALY NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 323. ITALY NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 324. ITALY NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 325. ITALY NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 326. ITALY NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 327. ITALY NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 328. ITALY NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 329. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 330. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 331. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 332. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 333. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 334. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 335. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 336. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 337. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 338. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 339. NIGERIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 340. NIGERIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 341. NIGERIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 342. NIGERIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 343. NIGERIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 344. NIGERIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 345. NIGERIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 346. NIGERIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 347. NIGERIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 348. NIGERIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 349. NORWAY NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 350. NORWAY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 351. NORWAY NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 352. NORWAY NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 353. NORWAY NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 354. NORWAY NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 355. NORWAY NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
• TABLE 356. NORWAY NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 357. NORWAY NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 358. NORWAY NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 359. POLAND NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 360. POLAND NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
• TABLE 361. POLAND NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 362. POLAND NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
• TABLE 363. POLAND NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
• TABLE 364. POLAND NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2

The Neuroscience Market was valued at USD 13.77 billion in 2023, expected to reach USD 15.11 billion in 2024, and is projected to grow at a CAGR of 10.34%, to USD 27.42 billion by 2030.

The scope of neuroscience as a market research domain encompasses the study and application of biological and cognitive sciences to understand and enhance human brain function. This field's necessity arises from growing demand for solutions to treat neurological disorders, mental health challenges, and degenerative diseases. Applications span pharmaceuticals, biotechnology, cognitive neuroscience, and neurotechnology, with end-use sectors including healthcare, education, and defense. Market growth is influenced by factors such as technological advancements in brain imaging, increased funding for neurological research, and a heightened focus on mental health awareness. The influx of artificial intelligence and machine learning technologies presents significant opportunities for innovation, such as personalized treatment plans and predictive analytics in mental health care. Furthermore, the expansion of telehealth services amid the COVID-19 pandemic has accelerated integration of neuroscience-driven applications in remote care settings. However, challenges persist, including high R&D costs, regulatory hurdles, and ethical considerations surrounding neurotechnological advancements. Additionally, the market is fragmented, with a few dominant players and numerous niche developers, adding competitive pressure. Areas ripe for innovation include developing non-invasive neurostimulation techniques, enhancing brain-computer interface technologies, and exploring the therapeutic potential of psychedelic substances and their neural impact. Business growth can be further bolstered by leveraging collaborations with universities and research institutions, fostering interdisciplinary research, and prioritizing patient-centric approaches in product development. As the market is inherently dynamic and rapidly evolving, staying ahead requires companies to remain vigilant of emerging trends and regulatory changes. The nature of the neuroscience market is therefore characterized by high innovation potential, tempered by challenges in monetization and ethical deployment, necessitating a strategic blend of research focus and market agility.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neuroscience Market

The Neuroscience Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of neurological disorders worldwide
  • Rise in drug discovery and development for neurological conditions
  • Increasing use of neuroscience to enhance brain health and cognitive functions
• Market Restraints
  • High cost associated with neuroscience research
• Market Opportunities
  • Emerging use of neuroscience in the development of personalized medicine
  • Favorable funding landscape for neuroscience research
• Market Challenges
  • Functional limitations pertaining to the use of neurotechnologies

Porter's Five Forces: A Strategic Tool for Navigating the Neuroscience Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neuroscience Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neuroscience Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neuroscience Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neuroscience Market

A detailed market share analysis in the Neuroscience Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neuroscience Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neuroscience Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neuroscience Market

A strategic analysis of the Neuroscience Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuroscience Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Bayer AG, Bio-Rad Laboratories, Inc., Brain Products GmbH, Compumedics Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilson, Inc., GL Sciences Inc., Hitachi, Ltd., Illumina, Inc., JASCO Corporation, Merck KGaA, Metrohm AG, Natus Medical Incorporated, Novasep Holding SAS, PerkinElmer Inc., Pfizer Inc., Promega Corporation, QIAGEN GmbH, Restek Corporation, Shimadzu Corporation, Siemens AG, Thermo Fisher Scientific Inc., Waters Corporation, and YMC Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Neuroscience Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Diagnostic Solution, Drug Therapy, and Non-drug Therapy. The Diagnostic Solution is further studied across Molecular and Non-molecular. The Molecular is further studied across Immunoassay, Instruments, Kits & Consumables, Liquid Chromatography, PCR, Sequencing, and Software. The Non-molecular is further studied across Brainstem auditory evoked potential, Electroencephalography, and Imaging. The Drug Therapy is further studied across Neurological disorders and Neuropsychiatric disorders. The Neurological disorders is further studied across Alzheimer's disease, Epilepsy, Huntington's disease, Multiple sclerosis, Parkinson's disease, and Vascular dementia. The Neuropsychiatric disorders is further studied across Anxiety, Attention deficit, Autism spectrum, Insomnia, Mood disorder, and Substance abuse. The Non-drug Therapy is further studied across Behavioral Therapy and Digital Health Services. The Behavioral Therapy is further studied across Animal-assisted, Home-based, Inpatient, and Outpatient.
• Based on End-User, market is studied across Diagnostic Laboratories, Hospitals, and Research & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of neurological disorders worldwide
    • 5.1.1.2. Rise in drug discovery and development for neurological conditions
    • 5.1.1.3. Increasing use of neuroscience to enhance brain health and cognitive functions
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with neuroscience research
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging use of neuroscience in the development of personalized medicine
    • 5.1.3.2. Favorable funding landscape for neuroscience research
  • 5.1.4. Challenges
    • 5.1.4.1. Functional limitations pertaining to the use of neurotechnologies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Neuroscience Market, by Type

• 6.1. Introduction
• 6.2. Diagnostic Solution
  • 6.2.1. Molecular
    • 6.2.1.1. Immunoassay
    • 6.2.1.2. Instruments
    • 6.2.1.3. Kits & Consumables
    • 6.2.1.4. Liquid Chromatography
    • 6.2.1.5. PCR
    • 6.2.1.6. Sequencing
    • 6.2.1.7. Software
  • 6.2.2. Non-molecular
    • 6.2.2.1. Brainstem auditory evoked potential
    • 6.2.2.2. Electroencephalography
    • 6.2.2.3. Imaging
• 6.3. Drug Therapy
  • 6.3.1. Neurological disorders
    • 6.3.1.1. Alzheimer's disease
    • 6.3.1.2. Epilepsy
    • 6.3.1.3. Huntington's disease
    • 6.3.1.4. Multiple sclerosis
    • 6.3.1.5. Parkinson's disease
    • 6.3.1.6. Vascular dementia
  • 6.3.2. Neuropsychiatric disorders
    • 6.3.2.1. Anxiety
    • 6.3.2.2. Attention deficit
    • 6.3.2.3. Autism spectrum
    • 6.3.2.4. Insomnia
    • 6.3.2.5. Mood disorder
    • 6.3.2.6. Substance abuse
• 6.4. Non-drug Therapy
  • 6.4.1. Behavioral Therapy
    • 6.4.1.1. Animal-assisted
    • 6.4.1.2. Home-based
    • 6.4.1.3. Inpatient
    • 6.4.1.4. Outpatient
  • 6.4.2. Digital Health Services

7. Neuroscience Market, by End-User

• 7.1. Introduction
• 7.2. Diagnostic Laboratories
• 7.3. Hospitals
• 7.4. Research & Academic Institutes

8. Americas Neuroscience Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Neuroscience Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Neuroscience Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Agilent Technologies, Inc.
• 2. Bayer AG
• 3. Bio-Rad Laboratories, Inc.
• 4. Brain Products GmbH
• 5. Compumedics Limited
• 6. Eli Lilly and Company
• 7. F. Hoffmann-La Roche Ltd.
• 8. Gilson, Inc.
• 9. GL Sciences Inc.
• 10. Hitachi, Ltd.
• 11. Illumina, Inc.
• 12. JASCO Corporation
• 13. Merck KGaA
• 14. Metrohm AG
• 15. Natus Medical Incorporated
• 16. Novasep Holding SAS
• 17. PerkinElmer Inc.
• 18. Pfizer Inc.
• 19. Promega Corporation
• 20. QIAGEN GmbH
• 21. Restek Corporation
• 22. Shimadzu Corporation
• 23. Siemens AG
• 24. Thermo Fisher Scientific Inc.
• 25. Waters Corporation
• 26. YMC Co., Ltd.